支持脓毒症诊疗的医院结构与流程:一项多医院研究
该研究对密歇根医院医学安全联盟的51家医院在2020年和2022年两次发放脓毒症流程调查,其中48家提交脓毒症方案进行结构化审查。所有医院均使用至少一种质量改进方法,审计/反馈占98.0%(50/51),临床教育占68.6%(35/51);方案中采用Sepsis-1定义占18.8%(9/48)、Sepsis-2定义占31.3%(15/48),无一家采用Sepsis-3定义。所有医院均采用至少一种促进快速脓毒症治疗的流程,包括订单集96.1%(49/51)和/或在至少一个临床场所储备常用抗生素92.2%(47/51)。医院自我评估中出院前实践得分最低,包括认知障碍筛查2.0%(1/51)和提供预期性指导3.9%(2/51)。
要点
- 51家医院全部使用至少一种质量改进方法,审计/反馈98.0%(50/51)、临床教育68.6%(35/51)。
- 48家提交的脓毒症方案中,Sepsis-1定义18.8%(9/48)、Sepsis-2定义31.3%(15/48),无一家(0/48)使用Sepsis-3定义。
- 所有医院均采用至少一种快速治疗促进流程:订单集96.1%(49/51),至少一个临床场所储备常用抗生素92.2%(47/51)。
- 治疗方案包含抗菌药物指导68.8%(33/48)、液体复苏70.8%(34/48)、血管加压药使用62.5%(30/48)。
- 自我评估中出院前实践得分最低:认知障碍筛查仅2.0%(1/51)自评「擅长」,提供预期性指导仅3.9%(2/51)。
适用人群与场景
- 密歇根医院医学安全联盟的51家医院,其中92.2%(47/51)为非营利医院、88.2%(45/51)为城市医院、11.8%(6/51)为农村医院、80.4%(41/51)为教学医院。
研究设计与关键结果
- 研究设计为多医院质量改进联盟调查,51家医院在2020年和2022年两个时间点完成脓毒症流程调查,48家提交脓毒症方案进行结构化审查。
- 所有医院(51/51)均使用至少一种质量改进方法,包括审计/反馈98.0%(50/51)和/或临床教育68.6%(35/51)。
- 脓毒症方案采用的定义:Sepsis-1占18.8%(9/48),Sepsis-2占31.3%(15/48),无一家(0/48)采用Sepsis-3定义。
- 所有医院(51/51)使用至少一种促进快速脓毒症治疗的流程,包括订单集96.1%(49/51)和/或在至少一个临床场所储备常用抗生素92.2%(47/51)。
- 治疗方案包含抗菌药物指导68.8%(33/48)、液体复苏70.8%(34/48)、血管加压药使用62.5%(30/48)。
- 自我评估中出院前实践得分最低:认知障碍筛查仅2.0%(1/51)自评「擅长」,提供预期性指导仅3.9%(2/51)。
- 医疗保险和医疗补助服务中心的严重脓毒症和脓毒性休克管理集束化绩效与医院特征或脓毒症政策文件特征之间无有意义的关联。
证据类型、等级与局限
- 证据类型:多医院质量改进联盟调查(横断面调查,两个时间点)及脓毒症方案结构化审查。
- 局限:原文未报告局限性。
对床旁实践的改变
- 现有脓毒症流程侧重于早期识别和治疗,而非基于康复的实践。
- 医院未一致地将器官功能障碍标准纳入脓毒症定义。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To identify opportunities for improving hospital-based sepsis care and to inform an ongoing statewide quality improvement initiative in Michigan.
DESIGN: Surveys on hospital sepsis processes, including a self-assessment of practices using a 3-point Likert scale, were administered to 51 hospitals participating in the Michigan Hospital Medicine Safety Consortium, a Collaborative Quality Initiative sponsored by Blue Cross Blue Shield of Michigan, at two time points (2020, 2022). Forty-eight hospitals also submitted sepsis protocols for structured review.
SETTING: Multicenter quality improvement consortium.
SUBJECTS: Fifty-one hospitals in Michigan.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Of the included hospitals, 92.2% (n = 47/51) were nonprofit, 88.2% (n = 45/51) urban, 11.8% (n = 6/51) rural, and 80.4% (n = 41/51) teaching hospitals. One hundred percent (n = 51/51) responded to the survey, and 94.1% (n = 48/51) provided a sepsis policy/protocol. All surveyed hospitals used at least one quality improvement approach, including audit/feedback (98.0%, n = 50/51) and/or clinician education (68.6%, n = 35/51). Protocols included the Sepsis-1 (18.8%, n = 9/48) or Sepsis-2 (31.3%, n = 15/48) definitions; none (n = 0/48) used Sepsis-3. All hospitals (n = 51/51) used at least one process to facilitate rapid sepsis treatment, including order sets (96.1%, n = 49/51) and/or stocking of commonly used antibiotics in at least one clinical setting (92.2%, n = 47/51). Treatment protocols included guidance on antimicrobial therapy (68.8%, n = 33/48), fluid resuscitation (70.8%, n = 34/48), and vasopressor administration (62.5%, n = 30/48). On self-assessment, hospitals reported the lowest scores for peridischarge practices, including screening for cognitive impairment (2.0%, n = 1/51 responded "we are good at this") and providing anticipatory guidance (3.9%, n = 2/51). There were no meaningful associations of the Centers for Medicare and Medicaid Services' Severe Sepsis and Septic Shock: Management Bundle performance with differences in hospital characteristics or sepsis policy document characteristics.
CONCLUSIONS: Most hospitals used audit/feedback, order sets, and clinician education to facilitate sepsis care. Hospitals did not consistently incorporate organ dysfunction criteria into sepsis definitions. Existing processes focused on early recognition and treatment rather than recovery-based practices.
参考来源
- Lóser MK, Horowitz JK, England P, et al. Institutional Structures and Processes to Support Sepsis Care: A Multihospital Study. Crit Care Explor. 2023. PMID: 37954901. doi:10.1097/CCE.0000000000001004
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。